NCT01624974View on ClinicalTrials.gov

Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)

PHASE2CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

August 9, 2012

Primary Completion Date

May 5, 2014

Study Completion Date

May 5, 2014

Conditions

Asthma

Interventions

DRUG

MK-1029

MK-1029 150 mg tablets taken QD

DRUG

Placebo

Placebo tablets (matching the MK-1029 150 mg tablets) QD

DRUG

Montelukast (ML)

ML 10 mg tablets QD

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01624974 - Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011) | Biotech Hunter | Biotech Hunter